All News
Consequences of TNF inhibition (3.18.2022)
This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Iberdomide in Systemic Lupus Erythematosus
The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks.
Read Article
Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis
Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.
Read Article
Disappointment Behind Acute Gout Hospitalizations
Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management.
Read Article
Individualized Therapy in Ankylosing Spondylitis
Whether patients with ankylosing spondylitis (AS) would improve substantially with tumor necrosis factor (TNF) inhibitor therapy was predicted with moderate to high accuracy based only on a standard lab test and two measures of disease activity, researchers reported from a modeling study.
Read Article
Low Dose IL-2 Efficacy in Rheumatoid Arthritis
A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA).
Read Article
RheumNow Live is Coming to Town (3.11.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
Read Article
Could Anifrolumab Work in Lupus Nephritis?
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
Read Article
Kawasaki Disease Guideline from ACR and Vasculitis Foundation
The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of
Read Article
Combo MTX and Leflunomide in Psoriatic Arthritis
A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.
Read Article
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.
Read Article
Failed Osteoarthritis Pulse Ultrasound Study
A promising therapy aimed at halting and even reversing the pathology underlying osteoarthritis (OA) of the knee failed to show any benefit in a randomized trial.
Read Article
Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients
JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (IMV).
Read Article
Links:
Links:
Links:
